A new CAR T cell therapy engineered to target mutant calreticulin successfully depleted disease-driving cells in myelofibrosis xenografts and human organoid models, offering a precision immunotherapy approach to this incurable blood disorder. The selective depletion while sparing normal hematopoietic cells strengthens the translational pathway toward human clinical trials. β Photo by Peter Burdon on Unsplash (Unsplash License)
MD, MPH, PhD. Editor-in-Chief, Georgian Medical Journal (GMJ). Professor and Head, School of Public Health, David Tvildiani Medical University (DTMU), Tbilisi, Georgia. Chair, Public Health Institute of Georgia (PHIG). President, AccrΓ©ditation Sans FrontiΓ¨res (ASF), Paris. Secretary/Treasurer, UEMS Section of Public Health. WHO Consultant, Health and Migration, Geneva. Former Member, UN Secretary-General's Independent Accountability Panel for Every Woman, Every Child, Every Adolescent (IAP-EWEC, 2016β2021). ORCID: 0000-0001-7609-4515.
